Latest News in the pharma Industry

Research & Development

Macrolide Pharmaceuticals Scientific Founder publishes new findings on groundbreaking technology for novel macrolide antibiotics

Macrolide Pharmaceuticals Scientific Founder publishes new findings on groundbreaking technology for novel macrolide antibiotics

25 May 2016

The paper describes a innovative synthetic chemistry platform that enables access to novel macrolide antibiotics.

Read more 
Synergy Pharmaceuticals presents additional Phase III plecanatide data in CIC at DDW

Synergy Pharmaceuticals presents additional Phase III plecanatide data in CIC at DDW

22 May 2016

Both plecanatide 3 mg and 6 mg doses met the primary endpoint.

Read more 
Crown Bioscience launches HuScreen — a new high throughput service platform utilizing the largest available collection of PDX models

Crown Bioscience launches HuScreen — a new high throughput service platform utilizing the largest available collection of PDX models

19 May 2016

HuScreen will initially focus on popular indications such as colorectal, gastric, lung (small and non-small cell type), ovarian and breast cancer.

Read more 
FDA grants Genentech’s cancer immunotherapy Tecentriq Accelerated Approval for people with a specific type of advanced bladder cancer

FDA grants Genentech’s cancer immunotherapy Tecentriq Accelerated Approval for people with a specific type of advanced bladder cancer

18 May 2016

First and only anti-PDL1 cancer immunotherapy approved by the FDA.

Read more 
MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped early

MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped early

18 May 2016

Independent Data Monitoring Committee recommends stopping the trial early as it met the primary endpoint, significantly extending progression-free survival (PFS) compared to letrozole alone, at pre-planned interim analysis.

Read more 
AstraZeneca announces positive results from benralizumab Phase III programme in severe asthma

AstraZeneca announces positive results from benralizumab Phase III programme in severe asthma

17 May 2016

Benralizumab first AstraZeneca respiratory biologic to complete Phase III.

Read more 
New presentations at ATS 2016 reinforce OFEV efficacy, safety and tolerability across range of patients with IPF

New presentations at ATS 2016 reinforce OFEV efficacy, safety and tolerability across range of patients with IPF

16 May 2016

A new analysis of Phase III INPULSIS trials reinforces OFEV's slowing of disease progression in a composite endpoint involving lung function decline (FVC decrease >10%) and death.

Read more 
New Keytruda (pembrolizumab) data at 2016 ASCO Annual Meeting

New Keytruda (pembrolizumab) data at 2016 ASCO Annual Meeting

16 May 2016

Includes 3-year overall survival data in melanoma and updated overall survival data in non-small cell lung cancer, as well as updated findings in head and neck cancer.

Read more 
Major study confirms Novartis' Ultibro Breezhaler superiority over Seretide in preventing COPD exacerbations

Major study confirms Novartis' Ultibro Breezhaler superiority over Seretide in preventing COPD exacerbations

15 May 2016

Ultibro Breezhaler also significantly reduced the rate and prolonged the time to the first moderate or severe exacerbation, compared with Seretide.

Read more 
Veterinary medicine looking increasingly to human drugs to supplement treatment pipelines

Veterinary medicine looking increasingly to human drugs to supplement treatment pipelines

15 May 2016

Significant unmet needs within veterinary care are driving veterinarians to treat animals such as dogs, cats and horses by prescribing drugs intended for human use.

Read more 
BMS and AbbVie announce EC approval of Empliciti for the treatment of multiple myeloma in adults who have received at least one prior therapy

BMS and AbbVie announce EC approval of Empliciti for the treatment of multiple myeloma in adults who have received at least one prior therapy

12 May 2016

First and only immunostimulatory antibody approved in the European Union for multiple myeloma.

Read more 
LDC and Boehringer Ingelheim join forces to discover a novel approach for the treatment of schizophrenia

LDC and Boehringer Ingelheim join forces to discover a novel approach for the treatment of schizophrenia

11 May 2016

The novel approach builds on ground-breaking research results from Prof. Moritz Rossner and his team at the Max Planck Institute of Experimental Medicine in Göttingen.

Read more